New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annu...(pproximately 30% of patients donot achie...),Health

"Given that many people suffering from generalized anxiety disorder do not achieve an adequate response from current treatments, new treatment options are needed; specifically for those who are not suited for existing therapies or who are simply not benefiting enough from the previously available approaches," said Professor Martin Katzman, Assistant Professor at the University of Toronto, and the Northern Ontario School of Medicine, and lead investigator on the GAD long-term study presented today.
The following GAD studies were presented at the APA meeting:

-- Study 9 (Poster # NR3-138) -- In a 10-week (eight weeks active; two

weeks tapering discontinuation), multicenter, double-blind, parallel-

group study, 951 patients were randomized to receive SEROQUEL XR 50

mg/day, 150 mg/day, 300 mg/day, or placebo. The mean change from

baseline to week 8 in HAM-A total score was significantly greater for

SEROQUEL XR 50 mg/day (-13.31, p<0.001) and 150 mg/day (-13.54,

p<0.001), but not 300 mg/day (-11.87, p=0.24), versus placebo

(-11.10). HAM-A response(S) at week 8 was significantly higher for 50

mg/day (60.3%, p<0.05) and 150 mg/day (61.5%, p<0.05), but not for 300

mg/day (54.9%, p=0.37), versus placebo (50.7%). HAM-A remission(**) at

week 8 was significantly higher for 150 mg/day versus placebo (37.2%

versus 27.6%; p<0.05) and was 36.1% (p=0.08) and 28.6% (p=0.96), for 50

mg/day and 300 mg/day doses, respectively. The most common adverse

events (AEs) (greater than or equal to 5% and double the rate of

placebo in any SEROQUEL XR dose group)
'/>"/>